BioCentury | Sep 13, 2019
Finance

After single exit, Avalon seeks path forward for build-to-buy assets from GSK deal

With GSK effectively bowing out of a 2013 build-to-buy deal with Avalon Ventures after delivering just one exit, the VC is seeking to navigate a future for a handful of Phase I-ready programs it created...
BioCentury | Apr 12, 2019
Clinical News

Merrimack discontinues last clinical candidate

...cash and a 12-month operating loss of $65.6 million. MM-310 is a docetaxel nanoliposome targeting EPHA2...
...targeting IGF1R and HER3; and seribantumab is a human mAb against HER3. Targets: EPHA2 - EPH receptor A2...
...10a; TNFRSF10B (DR5; TRAILR2; CD262) - TNF receptor superfamily member 10b Brian Moy, Assistant Editor MM-310 Merrimack Pharmaceuticals Inc. EPH receptor A2 (EPHA2)...
BioCentury | Jun 29, 2018
Clinical News

Merrimack discontinues pancreatic cancer candidate after Phase II miss

...for solid tumors, with data expected next half. The product is a docetaxel nanoliposome targeting EPH receptor A2 (EPHA2)...
...survival (OS) and safety Status: Development discontinued Milestone: NA Jaime De Leon istiratumab (MM-141) MM-310 Seribantumab (MM-121, SAR256212) Merrimack Pharmaceuticals Inc. EPH receptor A2 (EPHA2) Erb-b2...
BioCentury | Jun 25, 2018
Clinical News

Merrimack falls on Phase II pancreatic cancer failure

...half. The product is a docetaxel nanoliposome targeting EPH receptor A2 (EPHA2). Jaime De Leon istiratumab (MM-141) MM-310 Seribantumab (MM-121, SAR256212) Merrimack Pharmaceuticals Inc. EPH receptor A2 (EPHA2) Erb-b2...
BioCentury | Mar 13, 2018
Distillery Therapeutics

Cancer

...EPHA2 agonist conjugated to paclitaxel could help treat triple-negative breast cancer (TNBC). Conjugation of an EPHA2...
...the generic chemotherapy paclitaxel and in vitro binding assays yielded a peptide-drug conjugate that bound EPHA2...
...Phase III testing to treat melanoma and Phase I/II testing to treat esophageal cancer. TARGET/MARKER/PATHWAY: EPH receptor A2 (EPHA2)...
BioCentury | Dec 22, 2017
Clinical News

Stemline reports additional Phase II data for SL-701 in GBM

...a cancer immunotherapy comprising synthetic short peptides against IL-13 receptor alpha 2 (IL-13RA2; IL-13R; CD213A2), EPH receptor A2 (EPHA2)...
...IL-13RA2; IL-13R; CD213A2); EPH receptor A2 (EPHA2); survivin (BIRC5) Description: Cancer immunotherapy comprising synthetic short peptides against IL-13RA2, EPHA2...
...reported preliminary data from the trial (see BioCentury, Jan. 6 ). Allison Johnson SL-701 Stemline Therapeutics Inc. University of Pittsburgh EPH receptor A2 (EPHA2) Interleukin-13...
BioCentury | Nov 15, 2017
Distillery Therapeutics

Neurology

INDICATION: Alzheimer's disease (AD) Patient sample and mouse studies suggest promoting the interaction of SORL1 with EPHA4 could help treat AD. In frontal cortical tissue samples from postmortem patients, levels of activated EPHA4 -- a...
BioCentury | Nov 8, 2017
Preclinical News

Team identifies new role for SORL1 in Alzheimer's disease

In a paper published in The Journal of Experimental Medicine , researchers at Sanford Burnham Prebys Medical Discovery Institute and colleagues showed that sortilin-related receptor 1 (SORL1; gp250; LR11) attenuates beta amyloid-induced neurodegeneration, suggesting a new...
BioCentury | Aug 17, 2017
Finance

Built to purpose

With almost 40 start-ups engaging in build-to-buy deals since 2013 and an average 2-4 years for up or down decisions, the next year could see a spate of acquisitions -- or options declined -- that...
BioCentury | Jun 9, 2017
Finance

Pedaling to the clinic

...a few more compounds where we'll get some first-in-man data." Preclinical programs include BDCs against EPH receptor A2 (EPHA2)...
Items per page:
1 - 10 of 62